InflaRx
Price & Volume
Stats
See more52W Range | $0.71-$2.77 |
Market Cap | $77.2M |
Shares Short | 2M |
Financials
See moreRevenue (12 Mos) | $62,839 |
Revenue Growth (YoY) | -80.8% |
Gross Profit (12 Mos) | -$5.1M |
Diluted EPS | -$0.76 |
News
See moreYahoo Finance • 14 days ago
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
Yahoo Finance • last month
After-Hours Biotech Watch: IFRX, ABCL, RLYB Among Notable Risers
Yahoo Finance • 2 months ago
InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
Yahoo Finance • 2 months ago
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
About
CEO | Dr. Niels C. Riedemann M.D., Ph.D. |
Address | Winzerlaer Str. 2, Jena, Germany, 07745 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 74 |
